Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases

Journal of Endodontics

Volumn 31, Issue 11, 2005, Pages 831-834

  Katz, Harmon ^a,b  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Bisphosphonates; Osteonecrosis

Indexed keywords

EID: 27644590803     PISSN: 00992399     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.don.0000186481.96169.cd     Document Type: Article

References (41)

1. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39:668-77.
2. Bisphosphonates. http://courses.washington.edu/bonephys/opbis.html (accessed August 1, 2005).
3. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs 2004;18:269-78.
4. Davis JC, Jr, Huang F, Maksymowych W. New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Rheum Dis Clin North Am 2003;29:481-94.
5. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;CD003474.
6. Eaton CL, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 2003;29:189-98.
7. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 2005;328:746-50.
8. Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis: a case report. Clin Nephrol 2004;61:63-7.
9. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003;23:649-54.
10. Teramoto S, Matsuse T, Ouchi Y. Increased cytokines and pamidronate-induced bone pain in adults with cystic fibrosis. Lancet 1999;353:750.
11. Robinson NA, Yeo JF. Bisphosphonates: a word of caution. Ann Acad Med Singapore 2004;33(Suppl):48-9.
12. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102; discussion 99-102.
13. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102; discussion 99-102.
14. Durie BG, Katz M, Crowley J Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102; discussion 99-102.
15. Viale PH, Lin A. Exposed bone in oral cavities. Clin J Oncol Nurs 2005;9:355-7.
16. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.
17. Purcell PM, Boyd IW. Bisphosphonates and Osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
18. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182:413-5.
19. Philipone E. Nonhealing extraction site. Gen Dent 2005;53:161, 163.
20. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738.
21. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:135.
22. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
23. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117:440-1.
24. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:259-60.
25. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
26. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004;62: 391-2.
27. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48:268.
28. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
29. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9.
30. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
31. Tarassoff P, Hei Y-j. Letter to the Editor. N Engl J Med 2005;353:99-102; discussion 99-102.
32. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 2004;62:763-4.
33. News FPS. Show #34, December 2004. Available for viewing at http://www.access-data.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=276.
34. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003;8:12-37.
35. Bambini F, De Stefano CA, Giannotti L, Meme L, Pellecchia M. [Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)]. Minerva Stomatol 2003;52: 331-8.
36. Yoshinari M, Oda Y, Inoue T, Matsuzaka K, Shimono M. Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants. Biomaterials 2002;23:2879-85.
37. Yaffe A, Kollerman R, Bahar H, Binderman I. The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 2003;74:44-50.
38. Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 2004;351:190-2; author reply 190-2.
39. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
40. Sarathy A, Bourgeois S, Goodell G. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 2005;31:759-763.
41. Novartis PC. Important drug precaution for dental health professionals with patients being treated for cancer [letter to dentists]. Rockville, MD: US Food and Drug Administration; 2005 May 5. Available: http://www.fda.gov/ medwatch/safety/2005/safety05.htm-zometa2 (accessed: August 1, 2005).